↓ Skip to main content

Dove Medical Press

Article Metrics

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

Overview of attention for article published in Vascular Health and Risk Management, June 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
54 Mendeley
Title
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
Published in
Vascular Health and Risk Management, June 2012
DOI 10.2147/vhrm.s30064
Pubmed ID
Authors

Peter Bramlage, Turpie, Schmidt, Reinhold Kreutz, Michael Lassen, Jamal, Mantovani

Abstract

Venous thromboembolism is a frequent and potentially life-threatening complication of orthopedic surgery. Rivaroxaban is an oral direct factor Xa inhibitor, which was shown to be effective for the prevention of venous thromboembolism after elective hip and knee arthroplasty in the RECORD study program. Rivaroxaban has the potential to overcome the limitations of the current standards of care in the prevention of venous thromboembolism. XAMOS (Xarelto(®) in the prophylaxis of post-surgical venous thromboembolism after elective major orthopedic surgery of hip or knee) is an international, noninterventional, parallel-group study to gain insight into the safety (major bleeding, side effects) and effectiveness (prevention of symptomatic thromboembolic events) of rivaroxaban in daily clinical practice. XAMOS will follow 15,000 patients after major orthopedic surgery in approximately 200 centers worldwide, with about 7500 patients receiving rivaroxaban and about 7500 standard of care. XAMOS will supplement the clinical data obtained in the Phase III RECORD 1, 2, 3, and 4 trials in which rivaroxaban was shown to be superior for the primary efficacy endpoints, and with a safety profile similar to that of enoxaparin after hip or knee replacement surgery. XAMOS was started in 2009 and will complete recruitment and follow-up in 2011.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Andorra 1 2%
France 1 2%
Slovenia 1 2%
Unknown 51 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 20%
Other 8 15%
Student > Postgraduate 7 13%
Researcher 4 7%
Lecturer 3 6%
Other 11 20%
Unknown 10 19%
Readers by discipline Count As %
Medicine and Dentistry 33 61%
Nursing and Health Professions 3 6%
Agricultural and Biological Sciences 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Economics, Econometrics and Finance 1 2%
Other 1 2%
Unknown 11 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2018.
All research outputs
#4,938,316
of 16,569,218 outputs
Outputs from Vascular Health and Risk Management
#185
of 631 outputs
Outputs of similar age
#37,243
of 130,382 outputs
Outputs of similar age from Vascular Health and Risk Management
#4
of 15 outputs
Altmetric has tracked 16,569,218 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 631 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 130,382 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.